Share-Based Payment Arrangements (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Share-based Payment Arrangements [Abstract] |
|
| Schedule of Number and Weighted Average Exercise Prices of Share Options |
The number and weighted average exercise prices (in USD) of share options are as follows:
| | |
Weighted average exercise price | | |
Number of options | |
| | |
2025 | | |
2024 | | |
2023 | | |
2025 | | |
2024 | | |
2023 | |
| Outstanding on January 1 | |
| 0.36 | | |
| 0.46 | | |
| 0.52 | | |
| 20,364,323 | | |
| 19,218,783 | | |
| 18,468,235 | |
| Expired and forfeited during the year | |
| 0.35 | | |
| 0.84 | | |
| 0.54 | | |
| (4,628,747 | ) | |
| (2,004,460 | ) | |
| (2,026,452 | ) |
| Granted during the year | |
| 0.003 | | |
| 0.037 | | |
| 0.19 | | |
| 65,450,000 | | |
| 3,150,000 | | |
| 2,777,000 | |
| Outstanding on December 31 | |
| 0.071 | | |
| 0.36 | | |
| 0.46 | | |
| 81,185,576 | | |
| 20,364,323 | | |
| 19,218,783 | |
| Exercisable on December 31 | |
| 0.404 | | |
| 0.45 | | |
| 0.62 | | |
| 13,449,701 | | |
| 14,420,406 | | |
| 10,923,032 | |
|
| Schedule of Number of RSUs |
The number of RSUs are as follows:
| | |
Number of RSUs | |
| | |
2025 | | |
2024 | |
| Outstanding at January 1 | |
| 4,918,917 | | |
| 5,770,750 | |
| Granted during the year | |
| 62,450,000 | | |
| 3,150,000 | |
| Forfeited during the year | |
| (250,000 | ) | |
| (859,584 | ) |
| Vested during the year | |
| (2,596,075 | ) | |
| (3,142,249 | ) |
| Outstanding at December 31 | |
| 64,522,842 | | |
| 4,918,917 | |
|
| Schedule of Assumptions were Used |
The following assumptions were used:
| | |
2025 | | |
2024 | |
| Share Price - USD | |
| 0.0029-0.012 | | |
| 0.36 | |
| Exercise price - USD | |
| 0.003-0.012 | | |
| 0.37 | |
| Expected volatility (%) | |
| 98.7-113.13 | | |
| 95.93 | |
| Expected duration (years) | |
| 2-2.8 | | |
| 2-2.8 | |
| Dividend yield (%) | |
| - | | |
| - | |
| Risk free rate interest rate (%) | |
| 3.66%-3.93 | % | |
| 3.88 | % |
|
| Schedule of Expenses Recognized in the Consolidated Financial Statements |
Expenses recognized in the consolidated financial statements:
| | |
For the year ended December 31, | |
| | |
2025 | | |
2024 | | |
2023 | |
| | |
USD thousands | |
| Research and development expenses | |
| 113 | | |
| 117 | | |
| 768 | |
| General and administrative expenses | |
| 196 | | |
| 465 | | |
| 1,107 | |
| | |
| | | |
| | | |
| | |
| Total share-based expense recognized | |
| 309 | | |
| 582 | | |
| 1,875 | |
|